Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
Biogen, Eisai hit hard as Alzheimer’s drug is abandonedThe dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, Share XBiogen, Eisai hit hard as Alzheimer’s drug is abandonedhttps://pharmaphorum.com/news/biogen-eisai-hit-hard-as-alzheimers-drug-is-abandoned/
AbbVie upscales Voyager alliance with new target, more cashAbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease Share XAbbVie upscales Voyager alliance with new target, more cashhttps://pharmaphorum.com/news/abbvie-upscales-voyager-alliance-with-new-target-more-cash/
Alector kicks off biotech IPOs after US government shutdownThe 35-day US government shutdown has not just played havoc at government-run agencies – it has had a Share XAlector kicks off biotech IPOs after US government shutdownhttps://pharmaphorum.com/news/alector-kicks-off-biotech-ipos-after-us-government-shutdown/
R&D roundup: the ups and downs of CRISPR and Alzheimer’sWhile the controversy surrounding Vertex Pharma’s cystic fibrosis drug in the UK grows more intense, the US firm Share XR&D roundup: the ups and downs of CRISPR and Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-the-ups-and-downs-of-crispr-and-alzheimers/
Roche cancels two phase III Alzheimer’s trialsRoche and AC Immune have discontinued phase III trials of their Alzheimer’s disease drug crenezumab after an interim Share XRoche cancels two phase III Alzheimer’s trialshttps://pharmaphorum.com/news/roche-cancels-two-phase-iii-alzheimers-trials/
United Neuroscience inches closer to Alzheimer’s vaccine prizeA vaccine for Alzheimer’s disease developed by United Neuroscience has cleared a phase IIa trial, and seems to Share XUnited Neuroscience inches closer to Alzheimer’s vaccine prizehttps://pharmaphorum.com/news/united-neuroscience-alzheimers-vaccine/
BioXcel’s agitation drug gets FDA Fast TrackThe FDA has granted Fast Track Designation to BioXcel Therapeutics’ BXCL501 for the treatment of acute agitation resulting Share XBioXcel’s agitation drug gets FDA Fast Trackhttps://pharmaphorum.com/news/bioxcels-agitation-drug-gets-fda-fast-track/
Lilly focuses on tau with AC Immune Alzheimer’s R&D tie-upEli Lilly has paid $81m to develop drugs targeting aggregation of tau proteins associated with Alzheimer’s with Swiss Share XLilly focuses on tau with AC Immune Alzheimer’s R&D tie-uphttps://pharmaphorum.com/news/lilly-focuses-on-tau-with-ac-immune-alzheimers-rd-tie-up/
